生命科学资讯

What To Expect From Agilent's (A) Q4 Earnings - Finviz

The Bull Case For Illumina (ILMN) Could Change Following Buybacks And NovaSeq X Roadmap Reveal – Learn Why - simplywall.st

‘The perfect partner’: Astellas, Vir engage in $1.7B deal for masked prostate cancer bispecific

Waters Corporation to Present at the TD Cowen Health Care Conference - lelezard.com

FDA fleshes out new roadmap for testing personalized therapies

Astellas pays $240M cash for Vir's prostate cancer drug

Waters Corporation to Present at the TD Cowen Health Care Conference - Yahoo Finance

Agilent CFO joins TD Cowen’s 46th Health Care Conference chat - Stock Titan

Agilent to Participate in TD Cowen’s 46th Annual Health Care Conference - Business Wire

Thermo Fisher Datavant Data Link Draws Focus To TMO Valuation And Risks - simplywall.st

QurAlis' ALS drug sees early positive signal, but questions remain

Angelini nocks an AI arrow with $120M Quiver Bioscience deal

UPDATED: FDA illuminates new approval pathway for bespoke gene editing therapies

Swiss Rockets buys MGI subsidiary Complete Genomics after Biosecure Act

Fortress to sell priority review voucher for $205M

FDA Approval Deepens Agilent Role In KEYTRUDA Ovarian Cancer Testing - simplywall.st

Agilent Technologies (A) Stock Analysis: A Promising 38% Upside In The Healthcare Sector - DirectorsTalk Interviews

Waters Corporation (WAT) Stock Analysis: Unlocking 19.42% Potential Upside in the Healthcare Diagnostics Sector - DirectorsTalk Interviews

Illumina, Inc. (ILMN) Stock Analysis: Exploring a 15.62% Potential Upside in the Genomics Sector - DirectorsTalk Interviews

Novo’s next-gen obesity shot fails to match Lilly drug in head-to-head study